These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 1741813)
1. Sustained plasma concentrations of fluoxetine and/or norfluoxetine four and eight weeks after fluoxetine discontinuation. Pato MT; Murphy DL; DeVane CL J Clin Psychopharmacol; 1991 Jun; 11(3):224-5. PubMed ID: 1741813 [No Abstract] [Full Text] [Related]
2. Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder? Koran LM; Cain JW; Dominguez RA; Rush AJ; Thiemann S Am J Psychiatry; 1996 Nov; 153(11):1450-4. PubMed ID: 8890679 [TBL] [Abstract][Full Text] [Related]
3. Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administration. Renshaw PF; Guimaraes AR; Fava M; Rosenbaum JF; Pearlman JD; Flood JG; Puopolo PR; Clancy K; Gonzalez RG Am J Psychiatry; 1992 Nov; 149(11):1592-4. PubMed ID: 1415832 [TBL] [Abstract][Full Text] [Related]
4. Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. Amsterdam JD; Fawcett J; Quitkin FM; Reimherr FW; Rosenbaum JF; Michelson D; Hornig-Rohan M; Beasley CM Am J Psychiatry; 1997 Jul; 154(7):963-9. PubMed ID: 9210747 [TBL] [Abstract][Full Text] [Related]
5. Relationship between antidepressant response and plasma concentrations of fluoxetine and norfluoxetine. Norman TR; Gupta RK; Burrows GD; Parker G; Judd FK Int Clin Psychopharmacol; 1993; 8(1):25-9. PubMed ID: 8473717 [TBL] [Abstract][Full Text] [Related]
13. Fluoxetine and norfluoxetine plasma levels after treatment discontinuation in man. Vandel S; Bertschy G; Bouquet S; Bonin B; Vittouris N Therapie; 1994; 49(2):141-2. PubMed ID: 7817338 [No Abstract] [Full Text] [Related]
14. Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine: sources of variability and preliminary observations on relations with clinical response. Jannuzzi G; Gatti G; Magni P; Spina E; Pacifici R; Zuccaro P; Torta R; Guarneri L; Perucca E Ther Drug Monit; 2002 Oct; 24(5):616-27. PubMed ID: 12352933 [TBL] [Abstract][Full Text] [Related]
15. Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding. Kim J; Riggs KW; Misri S; Kent N; Oberlander TF; Grunau RE; Fitzgerald C; Rurak DW Br J Clin Pharmacol; 2006 Feb; 61(2):155-63. PubMed ID: 16433870 [TBL] [Abstract][Full Text] [Related]
16. Fluoxetine treatment of obsessive-compulsive disorder: an open clinical trial. Liebowitz MR; Hollander E; Schneier F; Campeas R; Hatterer J; Papp L; Fairbanks J; Sandberg D; Davies S; Stein M J Clin Psychopharmacol; 1989 Dec; 9(6):423-7. PubMed ID: 2687337 [TBL] [Abstract][Full Text] [Related]
17. Determination of fluoxetine and norfluoxetine by high-performance liquid chromatography. Wong SH; Dellafera SS; Fernandes R; Kranzler H J Chromatogr; 1990 Jan; 499():601-8. PubMed ID: 2324217 [TBL] [Abstract][Full Text] [Related]
18. Open trial of fluoxetine in obsessive-compulsive disorder. Jenike MA; Buttolph L; Baer L; Ricciardi J; Holland A Am J Psychiatry; 1989 Jul; 146(7):909-11. PubMed ID: 2787123 [TBL] [Abstract][Full Text] [Related]
19. Determination of the antidepressant fluoxetine and its metabolite norfluoxetine in serum by reversed-phase HPLC with ultraviolet detection. Orsulak PJ; Kenney JT; Debus JR; Crowley G; Wittman PD Clin Chem; 1988 Sep; 34(9):1875-8. PubMed ID: 3262022 [TBL] [Abstract][Full Text] [Related]